Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

The association between the poly(A) polymorphism in the VDR gene and cancer risk: a meta-analysis

Authors: Jin Huang, Jiqiao Yang, Haichuan Wang, Tianyuan Xiong, Hongbo Zhang, Yaxian Ma, Xiaoze Wang, Jichong Huang, Liang Du

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

The poly(A) polymorphism (L/S) in the VDR gene has been implicated in susceptibility of cancer, but a number of studies have reported inconclusive results. The aim of this study is to investigate the relationship between the poly(A) polymorphism in the VDR gene and cancer risk by meta-analysis. We searched PubMed database, EMBASE database, CNKI database, and Wanfang database, covering all studies until January 22, 2013. Statistical analysis was performed by using the software Revman4.2 and STATA 10.0. A total 8,186 cancer cases and 8,685 controls in 19 case–control studies from 15 studies were identified for data analysis. The results suggested that the S allele carriers (SS + SL) did not have an increased or decreased risk of cancer when compared with the homozygote LL carriers (odds ratio (OR) = 0.96, 95 % CI = 0.87–1.06, P = 0.43 for SS + SL vs. LL). In addition, in the subgroup analysis by ethnicity and cancer type, no significant association was found among Caucasians, African-Americans, prostate cancer, or breast cancer. This current meta-analysis suggested that the poly(A) polymorphism in the VDR gene may not contribute to the risk of cancer. Future studies are needed to validate our findings.
Appendix
Available only for authorised users
Literature
1.
DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20.PubMedCrossRef
2.
Yang S, Jia C, Zhu H, Han S. Cyp1a1 ile462val polymorphism and cervical cancer: evidence from a meta-analysis. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33:2265–72.CrossRef
3.
Chang CK, Mulholland H, Cantwell M, Anderson L, Johnston B, McKnight A, et al. Vitamin D receptor gene variants and esophageal adenocarcinoma risk: a population-based case–control study. J Gastrointest Cancer. 2012;43:512–7.PubMedCrossRef
4.
Wedren S, Magnusson C, Humphreys K, Melhus H, Kindmark A, Stiger F, et al. Associations between androgen and vitamin D receptor microsatellites and postmenopausal breast cancer. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007;16:1775–83.CrossRef
5.
Bai YH, Lu H, Hong D, Lin CC, Yu Z, Chen BC. Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World J Gastroenterol. 2012;18:1672.PubMedCrossRef
6.
Arjumand W, Ahmad ST, Seth A, Saini AK, Sultana S. Vitamin D receptor FOKI and BSMI gene polymorphism and its association with grade and stage of renal cell carcinoma in North Indian population. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33:23–31.CrossRef
7.
Zhuo X, Zhao H, Chang A, Ye H, Zhou Y, Song Y, et al. Cytochrome p450 1a1 ile462val polymorphism and oral carcinoma risk: an updated meta-analysis including 1,515 cases and 2,233 controls. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33:2079–89.CrossRef
8.
Zhang H, Xu Y, Zhang Z, Li L. The hogg1 ser326cys polymorphism and prostate cancer risk: a meta-analysis of 2584 cases and 3234 controls. BMC Cancer. 2011;11:391.PubMedCrossRef
9.
Liu J, Liao Q, Zhang Y, Sun S, Zhong C, Liu X. Cyclin d1 g870a polymorphism and lung cancer risk: a meta-analysis. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33:1467–76.CrossRef
10.
Blazer DG, Umbach DM, Bostick RM, Taylor JA. Vitamin D receptor polymorphisms and prostate cancer. Mol Carcinog. 2000;27:18–23.PubMedCrossRef
11.
Chakraborty A, Mishra AK, Soni A, Regina T, Mohil R, Bhatnagar D, et al. Vitamin D receptor gene polymorphism(s) and breast cancer risk in North Indians. Cancer Detect Prev. 2009;32:386–94.PubMedCrossRef
12.
Cheteri MBK, Stanford JL, Friedrichsen DM, Peters MA, Iwasaki L, Langlois MC, et al. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate. 2004;59:409–18.PubMedCrossRef
13.
Correa-Cerro L, Berthon P, Häussler J, Bochum S, Drelon E, Mangin P, et al. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet. 1999;105:281–7.PubMedCrossRef
14.
Flügge J, Laschinski G, Roots I, Krusekopf S. Vitamin D receptor poly(A) microsatellite and colorectal cancer risk in caucasians. Int J Colorectal Dis. 2009;24:171–5.PubMedCrossRef
15.
Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10:5472–81.PubMedCrossRef
16.
Ingles SA, Garcia DG, Wang W, Nieters A, Henderson BE, Kolonel LN, et al. Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control. 2000;11:25–30.PubMedCrossRef
17.
Ingles SA, Ross RK, Yu MC, Haile RW, Irvine RA, La Pera G, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997;89:166–70.PubMedCrossRef
18.
Kibel AS, Isaasc SD, Isaacs WB, Bova GS. Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol. 1998;160:1405–9.PubMedCrossRef
19.
Oakley-Girvan I, Feldman D, Eccleshall TR, Gallagher RP, Wu AH, Kolonel LN, et al. Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev. 2004;13:1325–30.PubMed
20.
Rollison DE, Cole AL, Tung KH, Slattery ML, Baumgartner KB, Byers T, et al. Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern USA. Breast Cancer Res Treat. 2012;132(2):683–91.PubMedCrossRef
21.
Slattery ML, Samowitz W, Hoffman M, Ma KN, Levin TR, Neuhausen S. Aspirin, NSAIDS, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev. 2004;13:538–45.PubMed
22.
Trabert B, Malone KE, Daling JR, Doody DR, Bernstein L, Ursin G, et al. Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case–control study of Caucasian and African-American women. Breast Cancer Res. 2007;9:R84.PubMedCrossRef
23.
Barbisan G, Perez LO, Contreras A, Golijow CD. Tnf-alpha and il-10 promoter polymorphisms, hpv infection, and cervical cancer risk. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33:1549–56.CrossRef
24.
Naik NA, Bhat IA, Afroze D, Rasool R, Mir H, Andrabi SI, et al. Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India). Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33:833–9.CrossRef
Metadata
Title
The association between the poly(A) polymorphism in the VDR gene and cancer risk: a meta-analysis
Authors
Jin Huang
Jiqiao Yang
Haichuan Wang
Tianyuan Xiong
Hongbo Zhang
Yaxian Ma
Xiaoze Wang
Jichong Huang
Liang Du
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0724-0

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue

Research Article

Discussion of modifying stage IV gastric cancer based on Borrmann classification

Research Article

RETRACTED ARTICLE: Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset

Research Article

Hepatitis B virus infection status is an independent risk factor for multiple myeloma patients after autologous hematopoietic stem cell transplantation

Review

Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir

Research Article

Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma

Research Article

Association between the GSTP1 Ile105Val polymorphism and prostate cancer risk: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits